CClinicalTrials.gg
RecruitingNCT06628349Updated Nov 25, 2025

Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein

An interventional study of Whey Protein Isolate 90% and Soy Protein Isolate (90% Protein) in Protein Metabolism, sponsored by Texas A&M University. Recruiting at 1 site in United States. Open to participants aged 50 Years to 95 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.

Sponsored by Texas A&M University · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
50 Years to 95 Years
Sex
All
01

Study summary

The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal. The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal. The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.

Read the detailed description

The study will be conducted in sarcopenic and non-sarcopenic older adults, stratified into different age categories. A sip feeding model will be used as it is a good model to establish the anabolic capacity of meals. The researchers hypothesize that plant-based protein induces less protein anabolism, due to lower production of EAA and higher production of non-essential amino acids (NEAA) as compared to dairy protein. The NEAA kinetics will be different between the plant proteins as soy protein has relatively high levels of the NEAA arginine and Pea protein of aspartate/glutamate. The researchers results will guide future nutritional advice on replacing daily protein with plant-based proteins while keeping the overall effects on metabolism comparable for both the EAA and NEAA. The study will take place at the research facility of the Center for Translational Research on Aging and Longevity (CTRAL), Texas A\&M University located in the Human Clinical Research Building ) affiliated with Texas A\&M University. The study involves 1 screening visit of approx. 3 hours, and 4 study days. Some study procedures (e.g., body composition, skeletal muscle function, questionnaires) may be skipped if completed within the past 3 months at CTRAL. All data will be recorded in Case Report Form and stored in the Texas A\&M REDCap System. Subjects will be asked to arrive in the fasted state on all study days. Fasting prior to screening is not required. On the screening day, body weight, height, and body composition by Dual-energy X-ray absorptiometry (DXA) will be measured. In addition, The Six-Minute Walk Test (6MWT) and skeletal muscle function tests will be assessed at the end of each screening visit. Each study visit will begin with vital signs. Before administration of the feeding or the tracer solution, baseline blood will be collected for measurement of the natural enrichment of metabolites. After the baseline sample is collected, feeding will begin and will be followed by tracers of several compounds that may be administered by IV pulse. Participants will receive the liquid nutritional supplement as sip feeds every 20 minutes for 5 hours. The liquid nutrition supplements will contain the following proteins: (1) 45g of whey protein (dairy based), (2) 45g of soy protein (plant based), (3) 45g of pea protein (plant based), or (4) Placebo (water). Participants will have the option of adding sugar free (SF) vanilla syrup, SF caramel syrup, or SF chocolate syrup to their meals.

02

Conditions studied

  • Protein Metabolism

Browse trials for

Keywords

  • Prandial
  • Sarcopenia
  • Plant protein
  • Animal protein
03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 775 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Texas A&M University is the lead sponsor of 123 studies on the registry; 23 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 2 (29%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age 50-95 years old
  • Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only
  • Stable body-weight (±5%) for the past 3 months
  • Ability to walk, sit down, and stand up (independently or with walking assistance device)
  • Willingness to lay supine in bed for up to 6 hours
  • Willingness and ability to comply with the protocol

Exclusion criteria

Exclusion Criteria:

  • Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
  • History of untreated metabolic disease including hepatic or renal disorder
  • Presence of acute illness or metabolically unstable chronic illness
  • Hysterectomy
  • Active dependence of alcohol or drugs
  • Use of short course of oral corticosteroids within 4 weeks preceding study day
  • Current use of long-term oral corticosteroids
  • Use of protein or amino acids containing nutritional supplements within 5 days of the first study day
  • Presence of fever within the last 3 days
  • Planned elective surgery requiring 2 or more days of hospitalization during the entire study
  • (Possible) pregnancy
  • Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
  • Already enrolled in another clinical trial
  • Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
  • Known allergy to any of the components of the feeding (soy, pea, or whey - dairy)
  • Established daily diet of vegetarian / vegan composition
  • \<23 MoCa score
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Healthy male older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    Healthy female older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    Healthy male old older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    Healthy female old older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    Sarcopenic male old older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    Sarcopenic female old older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    COPD male older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

  • Experimental
    COPD female older adults

    Dietary Supplement: Whey Protein Isolate 90%. Commercially available Dietary Supplement: Soy Protein Isolate (90% Protein). Commercially available Dietary Supplement: Organic Pea Protein Isolate. Commercially available Dietary Supplement: Placebo - Water

    Dietary Supplement: Whey Protein Isolate 90% · Dietary Supplement: Soy Protein Isolate (90% Protein) · Dietary Supplement: Organic Pea Protein Isolate · Dietary Supplement: Placebo (Water)

Interventions

  • Dietary supplementWhey Protein Isolate 90%

    Commercially available animal based protein powders

  • Dietary supplementSoy Protein Isolate (90% Protein)

    Commercially available plant based protein powders

  • Dietary supplementOrganic Pea Protein Isolate

    Commercially available plant based protein powders

  • Dietary supplementPlacebo (Water)

    Normal drinking water

06

What researchers measure

Primary outcomes

  1. Protein and amino acid synthesis capacity of plant-based and animal-based protein in older adults with or without sarcopenia measured by the use of stable isotope tracers

    A novel stable isotope technique will be used to assess simultaneously the anabolic response and whole body production rates of a variety of amino acids to intake of both dietary proteins in sarcopenic older participants. The samples will be stored in laboratory freezers and the amino acid isotope enrichments and concentrations analyzed by Liquid Chromatography with tandem mass spectrometry (LC-MS/MS). The researchers will then conduct LC-MS/MS analysis, peak integration, calculation of amino acid concentrations and whole body productions from raw data, and use the results for preparation of papers for presentation, publication, and final reports. The researchers main hypothesis is that plant-based protein induces less protein anabolism, due to lower whole body production of essential amino acids (EAA) and higher production of non-essential amino acids (NEAA) as compared to dairy protein.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Texas A&M University - CTRAL
    College Station, Texas 77845, United States
    • Laura Ruebush · Contact · le.ruebush@ctral.org · 979-218-5515
    • Nicolaas E Deutz, MD, PhD · Principal investigator
    • Marielle P Engelen, PhD · Sub investigator
    Recruiting
08

References and documents

Publications

  • Huttl VN, Deutz N, Wierzchowska-McNew RA, Ruebush LE, Engelen M. Whole-body and intracellular arginine metabolism in hypertension: role of disease severity and sex. Am J Hypertens. 2026 May 18:hpag047. doi: 10.1093/ajh/hpag047. Online ahead of print. PubMed 42149813 ↗

Individual participant data

Plan to share: Undecided — Data may be shared upon request for up to 6 years beyond completion of the trial based on methods/proposals approved by both parties' institutional review committees. Individual participant data that underlie the results of the trial may be shared after de-identification (text, tables, figures, and appendices). Additional documents available per request include: study protocol, statistical analysis plan, and informed consent. Requests should be directed to Dr. Marielle Engelen (mpkj.engelen@ctral.org).

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06628349
Lead sponsor
Texas A&M University
Responsible party
Marielle PKJ Engelen, PhD (Professor, Texas A&M University) — Principal investigator
First posted
Oct 4, 2024
Start date
Feb 1, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 25, 2025

Study contacts

Marielle Engelen, PhD
Contact
mpkj.engelen@ctral.org
979-220-2282
Savanah Knezek, BS
Contact
research@ctral.org
979-442-8468
Marielle Engelen, PhD
principal investigator · Texas A&M University
Nicolaas Deutz, MD, PhD
principal investigator · Texas A&M University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion